2_Ghostwriting - Ross

2_Ghostwriting - Ross - SPECIAL COMMUNICATION Guest...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
SPECIAL COMMUNICATION Guest Authorship and Ghostwriting in Publications Related to Rofecoxib A Case Study of Industry Documents From Rofecoxib Litigation Joseph S. Ross, MD, MHS Kevin P. Hill, MD, MHS David S. Egilman, MD, MPH Harlan M. Krumholz, MD, SM A UTHORSHIP IN BIOMEDICAL publication provides recog- nition while establishing ac- countability and responsibil- ity. Guest authorship has been defined as the designation of an individual who does not meet authorship criteria as an author. 1,2 It was identified in 16% of re- search articles, 26% of review articles, and 21% of editorials in a survey of 6 peer-reviewed medical journals, 3 in ad- dition to 41% of Cochrane reviews. 4 Ghostwriting has been defined as the failure to designate an individual (as an author) who has made a substantial contribution to the research or writ- ing of a manuscript. 1 Ghostwriting was demonstrated in 13% of research ar- ticles, 10% of review articles, 6% of edi- torials, and 11% of Cochrane re- views 3,4 ; other research has found similar rates. 5 Two studies have characterized the practices of guest authorship and ghost- writing using industry documents, one examining practices related to gaba- pentin by Pfizer Inc and Parke-Davis, Division of Warner-Lambert Com-
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 10/10/2010 for the course ENG 000121 taught by Professor Mcgrand during the Spring '10 term at Cornell.

Ask a homework question - tutors are online